Risk management policy and black-box warnings: A qualitative analysis of US FDA proceedings

Drug Safety

Volumn 32, Issue 11, 2009, Pages 1057-1066

  Cook, Daniel M ^a   Gurugubelli, Rama K ^a   Bero, Lisa A ^b  

^a UNIVERSITY OF NEVADA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMPRENAVIR PHOSPHATE; ARIPIPRAZOLE; CIPROFLOXACIN; CONJUGATED ESTROGEN; DOCETAXEL; ESOMEPRAZOLE; ESTROGEN; IMATINIB; ISOTRETINOIN; LEVOFLOXACIN; METHYLPHENIDATE; MEVINOLIN; MINOCYCLINE; MODAFINIL; ONDANSETRON; PAROXETINE; POTASSIUM CHLORIDE; PRAVASTATIN; PROPOFOL; RANITIDINE; RIVASTIGMINE; TELITHROMYCIN; TETRAHYDROLIPSTATIN; VENLAFAXINE; VORICONAZOLE;

ADVISORY COMMITTEE; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DATA BASE; DEMENTIA; DRUG APPROVAL; DRUG LABELING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; LICENSING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RISK MANAGEMENT;

ADVISORY COMMITTEES; DRUG LABELING; HEALTH POLICY; HUMANS; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; RISK MANAGEMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70349972263     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11316670-000000000-00000     Document Type: Article

References (77)

1. Meltzer D. Risks and benefits of risk-management plans. Health Aff 2007 May/Jun; 26 (3): 681-683
2. Gottlieb S. Drug safety proposals and the intrusion of fed-eral regulation into patient freedom and medical practice. Health Aff 2007 May/Jun; 26 (3): 664-677
3. Avorn J. Drug warnings that can cause fits: communicating risks in a data-poor environment. N Engl J Med 2008 Sep 4; 359 (10): 991-994
4. Kanjanarat P, Winterstein AG, Johns TE, et al. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm 2003 Sep; 60: 1750-1759
5. Classen D. Medication safety: moving from illusion to rea-lity. JAMA 2003 Mar 5; 289 (9): 1154-1156
6. Classen DC, Metzger J. Improving medication safety: the measurement conundrum and where to start. Int J Qual Health Care 2003; 15 Suppl. I: i41-7
7. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med 2005 Jun 27; 165 (12): 1363-1369
8. Committee on the Assessment of the US Drug Safety Sys-tem. The future of drug safety: promoting and protecting the health of the public. Washington, DC: National Academies Press, 2006 9.
9. Gottlieb S. Opening pandora?s pillbox: using modern information tools to improve drug safety. Health Aff 2005 Jul/Aug; 24 (4): 938-949
10. Cullen D, Bates D, Small S, et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. Jt Comm J Qual Improv 1995 Oct; 21 (10): 549-552
11. Talbot JCC, Nilsson BS. Pharmacovigilance in the pharma-ceutical industry. Br J Clin Pharmacol 1998; 45: 427-431
12. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29 (5): 385-396
13. Brewer T, Colditz GA. Postmarketing surveillance and ad-verse drug reactions: current perspectives and future needs. JAMA 1999 Mar 3; 281 (9): 824-834
14. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med 2008 Mar 27; 358 (13): 1354-1361
15. Abraham J, Davis C. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy. Soc Sci Med 2005; 61 (5): 881-892
16. Furberg C, Levin A, Gross P, et al. The FDA and drug safety. Arch Intern Med 2006; 166: 1938-1942
17. Murphy S, Roberts R. "Black box" 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 2006; 117: 34-39
18. Karch AM. The gray areas of black box warnings: who is responsible for heeding them? Am J Nurs 2006 Jun; 106 (6): 77-78
19. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002 May 1; 287 (17): 2215-2220
20. Abroms L, Maibach E, Lyon-Daniel K, et al. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006 Nov; 3 (11): 1978-1983
21. Doshi AE. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of accutane (isotretinoin). Seton Hall Law Rev 2007; 37: 625-660
22. Roche Pharmaceuticals. Roche discontinues and plans to delist accutane in the US [press release; online]. Available from URL: http://www.rocheusa.com/ newsroom/current/2009/pr2009062601.html [Accessed 2009 Sep 4]
23. Garbe E, Andersohn F. Contraindication labelling changes in the United States and Germany. Eur J Clin Pharmacol 2007; 63 (1): 87-93
24. Furberg CD. Decisions by regulatory agencies: are they evidence-based? Trials 2007 Apr 11; 8 (1): 13 [online]. Available from URL: http://www. trialsjournal.com/content/ pdf/1745-6215-8-13.pdf [Accessed 2009 Sep 4]
25. Reggi V, Balocco-Mattavelli R, Bonati M, et al. Prescribing information in 26 countries: a comparative study. Eur J Clin Pharmacol 2003 Aug; 59 (4): 263-270
26. Vitry A, Lexchin J, Sasich L, et al. Provision of information on regulatory authorities? websites. Intern Med J 2008 Mar 11; 38 (7): 559-567
27. Steinbrook R. Science, politics, and federal advisory com-mittees. N Engl J Med 2004 Apr 1; 350 (14): 1454-1460
28. Roden DM, Temple R. The US Food and Drug Adminis-tration Cardiorenal Advisory Panel and the drug approval process. Circulation 2005 Apr 5; 111 (13): 1697-1702
29. Merrill RA. Modernizing the FDA: an incremental revolu-tion. Health Aff 1999 Mar/Apr; 18 (2): 96-111
30. Shamoo AE. Role of conflict of interest in public advisory councils. In: Cheney D, editor. Ethical issues in research. Frederick (MD): University Publishing Group, 1993; 159-174
31. Nguyen NT, Cook DM, Bero LA. The decision-making process of US Food and Drug Administration advisory committees on switches from prescription to over-the-counter status: a comparative case study. Clin Ther 2006 Aug; 28 (8): 1231-1243
32. Smith BLR. The advisers: scientists in the policy process. Washington, DC: The Brookings Institution, 1992
33. Ackerley N, Eyraud J, Mazzotta M. Measuring conflict of interest and expertise on FDA advisory committees, 2007 October 26 [online]. Available from URL: http://www.fda. gov/oc/advisory/ergcoireport.pdf [Accessed 2009 Mar 31]
34. Center for Drug Evaluation and Research. Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee, July 10 2008, Sheraton Washington North Hotel, Beltsville, Maryland: questions [online]. Available from URL http://www.fda.gov/ohrms/dockets/ ac/08/questions/2008-4372q1.pdf [Accessed 2009 Mar 31]
35. Neale T. Risks of suicidal ideation and behavior with epi-lepsy drugs reaffirmed. MedPage Today 2008 Jul 10 [online]. Available from URL: http://www.medpagetoday. com/Psychiatry/GeneralPsychiatry/10086 [Accessed 2009 Mar 31]
36. Creswell JW, Hanson WE, Plano VLC, et al. Qualitative research designs: selection and implementation. Counsel Psych 2007 Mar; 35 (2): 236-264
37. Sandelowski M. Real qualitative researchers do not count: the use of numbers in qualitative research. Res Nurs Health 2001 Jun; 24 (3): 230-240
38. Neuman WL. Social research methods: qualitative and quantitative approaches. 4th ed. Boston (MA): Allyn and Bacon, 2000
39. Food and Drug Administration Center for Drug Evalua-tion and Research. Psychopharmacologic Drugs Advisory Committee with the Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee 2004 February 2 [online]. Available from URL http://www.fda.gov/ohrms/dock ets/ac/04/transcripts/4006T1.pdf [Accessed 2009 Mar 31].
40. Food and Drug Administration Center for Drug Evaluation and Research. Anti-Infective Drugs Advisory Committee in Joint Session with the Drug Safety and Risk Management Advisory Committee 2006 December 15 [online]. Available from URL http://www.fda.gov/ohrms/dockets/ac/06/tran scripts/2006-4266t2-part1.pdf [Accessed 2009 Mar 31].
41. Food and Drug Administration Center for Drug Evalua-tion and Research. Psychopharmacologic Drugs Advisory Committee 2005 December 2 [online]. Available from URL http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4195T1.pdf [Accessed 2009 Mar 31].
42. Food and Drug Administration Center for Drug Evalua-tion and Research. Peripheral and Central Nervous System Drugs Advisory Committee 2006 May 17 [online]. Available from URL http://www.fda.gov/ohrms/dockets/ac/ 06/transcripts/2006-4216t1-transcript.pdf [Accessed 2009 Mar 31].
43. Food and Drug Administration Center for Drug Evalua-tion and Research. Psychopharmacologic Drugs Advisory Committee 2006 March 23 [online]. Available from URL http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4212T1.pdf [Accessed 2009 Mar 31].
44. Gerber BJ, Neeley GW. Perceived risk and citizen pre-ferences for governmental management of routine hazards. Policy Stud J 2005; 33 (3): 395-418
45. Shapiro SA, Glicksman RL. Risk regulation at risk. Stanford (CA): Stanford University Press, 2003
46. Hirst C, Cook S, Dai W, et al. A call for international har-monization in therapeutic risk management. Pharmaco-epidemiol Drug Saf 2006; 15 (12): 839-849
47. Jardine CG, Hrudey SE, Shortreed JH, et al. Risk manage-ment frameworks for human health and environmental risks. J Toxicol Environ Health B 2003; 6 (6): 569-718
48. Sunstein CR. Risk and reason: safety, law, and the en-vironment. New York: Cambridge University Press, 2002
49. Schierow L-J. The role of risk analysis and risk management in environmental protection. Washington, DC: Congressional Research Service, 2005 Mar 1
50. Andrews E, Dombeck M. The role of scientific evidence of risks and benefits in determining risk management policies for medications. Pharmacoepidemiol Drug Saf 2004; 13: 599-608
51. Epstein SS, Ashford NA, Blackwelder B, et al. The crisis in US and International Cancer Policy. Int J Health Serv 2002; 32 (4): 669-707
52. Callreus T. The precautionary principle and pharmaceutical risk management. Drug Saf 2005; 28 (6): 465-471
53. Lasser KE, Seger DL, Yu DT, et al. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med 2006 Feb 13; 166 (3): 338-344
54. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug pre-scribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006; 15 (6): 369-386
55. Aaronson DW. The "black box" warning and allergy drugs. J Allergy Clin Immunol 2006 Jan; 117 (1): 40-44
56. Stafford RS. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med 2008 Apr 3; 358 (14): 1427-1429
57. Psaty BM, Ray W. FDA guidance on off-label promotion and the state of the literature from sponsors. JAMA 2008 Apr 23; 299 (16): 1949-1951
58. Hampton T. Experts weigh in on promotion, prescription of off-label drugs. JAMA 2007 Feb 21; 297 (7): 683-684
59. Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008 Jan; 65 (1): 94-101
60. Food and Drug Administration. Prescription drug advertis-ing (21CFR202.1). US Government Printing Office 2008 [online]. Available from URL http://edocket.access.gpo.gov/cfr-2001/aprqtr/pdf/21cfr202.1.pdf [Accessed 2009 Sep 4]
61. Wright C, Schnoll S, Bernstein D. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective. Ann N Y Acad Sci 2008 Oct; 1141: 284-303
62. Thompson CA. Hospital inspectors eye black-box warn-ings. Am J Health Syst Pharm 2008 May 15; 65 (10): 890-894
63. Weatherby LB, Nordstrom BL, Fife D, et al. The impact of wording in "Dear doctor" letters and in black box labels. Clin Pharmacol Ther 2002 Dec; 72 (6): 735-742
64. Allen LaPointe NM, Pappas P, Deverka P, et al. Patient receipt and understanding of written information provided with isotretinoin and estrogen prescriptions. J Gen Intern Med 2007 Jan; 22 (1): 98-101
65. Shrank WH, Agney-Blais J, Choudhry NK, et al. The variability and quality of medication container labels. Arch Intern Med 2007 Sep 10; 167 (16): 1760-1765
66. Agency for Healthcare Research and Quality. CERTs annual report: year 4 2003 [online]. Available from URL http://www.ahrq.gov/clinic/certsrep4.pdf. [Accessed 2009 Aug 27].
67. US FDA, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for industry: development and use of risk minimization action plans. Rockville (MD): US DHHS, Food and Drug Administration, 2005
68. Kaufman M. FDA plans new board to monitor drug safety. The Washington Post 2005 Feb 16 [online]. Available from URL: http://www.washingtonpost.com/wp- dyn/articles/A25893-2005Feb15.html [Accessed 2009 Aug 7]
69. Bush JK, Dai WS, Dieck GS, et al. The art and science of risk management: a US research-based industry perspective. Drug Saf 2005; 28 (1): 1-18
70. Schultz WB. Bolstering the FDA?s drug-safety authority. N Engl J Med 2007 Nov 29; 357 (22): 2217-2219
71. Traynor K. Law gives FDA new enforcement clout. Am J Health Syst Pharm 2007 Nov 15; 64 (22): 2314-2315
72. Department of Health and Human Services. Identification of drug and biological products deemed to have risk evaluation and mitigation strategies for purposes of the Food and Drug Administration Amendments Act 2007. Fed Regist 2008 Mar 27; 73 (60) 16313-16314.
73. Department of Health and Human Services. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Fed Regist 2008; 73 (164): 49603-49610
74. Vlad I, Sallot LM, Reber BH. Rectification without assuming responsibility: testing the transgression flowchart with the Vioxx recall. J Public Relat Res 2006; 18 (4): 357-379
75. Abraham J. The science and politics of medicines control. Drug Saf 2003; 26 (3): 135-143
76. Subcommittee on Science and Technology of the FDA Science Board. FDA science and mission at risk 2007 November [online]. Available from URL http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4329b-02-01- FDA%20Report%20on%20Science%20and%20Technology.pdf [Accessed 2007 Dec 4].
77. Sarewitz D, Pielke Jr R, Keykhah M. Vulnerability and risk: some thoughts from a political and policy perspective. Risk Anal 2003; 23 (4): 805-810